Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease

Research output: Contribution to journalArticle

Standard

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. / Voevodskaya, Olga; Sundgren, Pia C.; Strandberg, Olof; Zetterberg, Henrik; Minthon, Lennart; Blennow, Kaj; Wahlund, Lars Olof; Westman, Eric; Hansson, Oskar.

In: Neurology, Vol. 86, No. 19, 10.05.2016, p. 1754-1761.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

Voevodskaya, Olga ; Sundgren, Pia C. ; Strandberg, Olof ; Zetterberg, Henrik ; Minthon, Lennart ; Blennow, Kaj ; Wahlund, Lars Olof ; Westman, Eric ; Hansson, Oskar. / Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. In: Neurology. 2016 ; Vol. 86, No. 19. pp. 1754-1761.

RIS

TY - JOUR

T1 - Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease

AU - Voevodskaya, Olga

AU - Sundgren, Pia C.

AU - Strandberg, Olof

AU - Zetterberg, Henrik

AU - Minthon, Lennart

AU - Blennow, Kaj

AU - Wahlund, Lars Olof

AU - Westman, Eric

AU - Hansson, Oskar

PY - 2016/5/10

Y1 - 2016/5/10

N2 - Objective: We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity. Methods: In this cross-sectional multicenter study (a subset of the prospective Swedish BioFINDER study), we included 4 groups, representing the different stages of predementia AD: (1) cognitively healthy elderly with normal CSF β-amyloid 42 (Aβ42), (2) cognitively healthy elderly with abnormal CSF Aβ42, (3) patients with subjective cognitive decline and abnormal CSF Aβ42, (4) patients with mild cognitive decline and abnormal CSF Aβ42 (N total 352). Spectroscopic markers measured in the posterior cingulate/precuneus were considered alongside known disease biomarkers: CSF Aβ42, phosphorylated tau, total tau, [18 F]-flutemetamol PET, f-MRI, and the genetic risk factor APOE. Results: Amyloid-positive cognitively healthy participants showed a significant increase in mI/creatine and mI/NAA levels compared to amyloid-negative healthy elderly (p <0.05). In amyloid-positive healthy elderly, mI/creatine and mI/NAA correlated with cortical retention of [18 F] flutemetamol tracer (0.44, p 0.02 and 0.51, p 0.01, respectively). Healthy elderly APOE ϵ4 carriers with normal CSF Aβ42 levels had significantly higher mI/creatine levels (p <0.001) than ϵ4 noncarriers. Finally, elevated mI/creatine was associated with decreased functional connectivity within the default mode network (r pearson-0.16, p 0.02), independently of amyloid pathology. Conclusions: mI levels are elevated already at asymptomatic stages of AD. Moreover, mI/creatine concentrations were increased in healthy APOE ϵ4 carriers with normal CSF Aβ42 levels, suggesting that mI levels may reveal regional brain consequences of APOE ϵ4 before detectable amyloid pathology.

AB - Objective: We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity. Methods: In this cross-sectional multicenter study (a subset of the prospective Swedish BioFINDER study), we included 4 groups, representing the different stages of predementia AD: (1) cognitively healthy elderly with normal CSF β-amyloid 42 (Aβ42), (2) cognitively healthy elderly with abnormal CSF Aβ42, (3) patients with subjective cognitive decline and abnormal CSF Aβ42, (4) patients with mild cognitive decline and abnormal CSF Aβ42 (N total 352). Spectroscopic markers measured in the posterior cingulate/precuneus were considered alongside known disease biomarkers: CSF Aβ42, phosphorylated tau, total tau, [18 F]-flutemetamol PET, f-MRI, and the genetic risk factor APOE. Results: Amyloid-positive cognitively healthy participants showed a significant increase in mI/creatine and mI/NAA levels compared to amyloid-negative healthy elderly (p <0.05). In amyloid-positive healthy elderly, mI/creatine and mI/NAA correlated with cortical retention of [18 F] flutemetamol tracer (0.44, p 0.02 and 0.51, p 0.01, respectively). Healthy elderly APOE ϵ4 carriers with normal CSF Aβ42 levels had significantly higher mI/creatine levels (p <0.001) than ϵ4 noncarriers. Finally, elevated mI/creatine was associated with decreased functional connectivity within the default mode network (r pearson-0.16, p 0.02), independently of amyloid pathology. Conclusions: mI levels are elevated already at asymptomatic stages of AD. Moreover, mI/creatine concentrations were increased in healthy APOE ϵ4 carriers with normal CSF Aβ42 levels, suggesting that mI levels may reveal regional brain consequences of APOE ϵ4 before detectable amyloid pathology.

UR - http://www.scopus.com/inward/record.url?scp=84978396743&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000002672

DO - 10.1212/WNL.0000000000002672

M3 - Article

C2 - 27164711

AN - SCOPUS:84978396743

VL - 86

SP - 1754

EP - 1761

JO - Neurology

JF - Neurology

SN - 1526-632X

IS - 19

ER -